Though human studies are lacking, preclinical trials support its potential in treating fractures
A new derivate of DOX, 4-acetyl-2-nitro-benzenesulfonyl doxorubicin (ANS-DOX) was synthesized and shown to be converted into DOX by MGST1 and GSTA1-1, whereas no activity was observed for GSTP1-1 128
It was effective, but it had its drawbacks: slower delivery, a smaller viewing screen, and a reputation for notable discomfort
At that dose, NAC has also been shown to improve glycaemic control, hormone levels and antioxidant status in this patient group, and longer-term supplementation may therefore be beneficial
Conclusion Research on BPC-157 and GHK-Cu cream has demonstrated promising preclinical findings in tissue repair and recovery
Consultation, Consent & Client Education Guidance Learn how to assess suitability, explain treatment benefits, manage expectations and confidently obtain informed consent before treatment